Bone Graft Materials/DBM

June 29, 2022

AlloSource Launches AlloFuse Micro Fiber Allograft

AlloSource Launches AlloFuse Micro Fiber Allograft
AlloFuse Micro Fibers are the latest addition to the AlloFuse line of Fibers and Fiber Boat products, expanding the company's portfolio.
May 3, 2022

SeaSpine Launches OsteoTorrent DBM Product Families

SeaSpine Launches OsteoTorrent DBM Product Families
OsteoTorrent putties are packaged and sterilized in a dry state and designed to improve osteoinductive potential and shelf-life.
April 5, 2022

TheraCell Acquired by Isto Biologics

TheraCell Acquired by Isto Biologics
The move will expand Isto's portfolio of procedure-specific allografts for spine, orthopedic and sports medicine applications.
March 7, 2022

Bone Biologics Partners with MTF to Supply DBM

Bone Biologics Partners with MTF to Supply DBM
Bone Biologics' rhNELL-1 bone graft substitute product will be supplied by MTF Biologics for the initiation and improvement of bone formation.
January 13, 2022

OssDsign to Collect Data on Catalyst Bone Graft

OssDsign to Collect Data on Catalyst Bone Graft
OssDsign will launch a U.S. clinical registry to collect real-world data on Catalyst in spinal fusion applications.
October 25, 2021

Neoss Launches NeoGenix XP Bone Substitute

Neoss Launches NeoGenix XP Bone Substitute
NeoGenix XP more closely resembles natural bone vs. synthetic materials, such as hydroxyapatite or tricalcium phosphate.
October 4, 2021

CoreBone Raises Funds for Bioactive Bone Graft

CoreBone Raises Funds for Bioactive Bone Graft
The investment will be used to extend CoreBone's commercial global presence, primarily in China, with coral-based bone graft.
September 7, 2021

Locate Bio Closes £10 Million Funding Round

Locate Bio Closes £10 Million Funding Round
Proceeds will further advance the company's regenerative medicine pipeline of orthobiologic products.
July 30, 2021

Bioventus to Acquire Misonix, Enhance Surgical Solutions

Bioventus to Acquire Misonix, Enhance Surgical Solutions
The merger will create a company positioned with products and specialized salesforces serving hospital, ambulatory surgical center and office care settings.
July 28, 2021

First U.S. Cases with Orthofix fiberFUSE Strip Bone Graft

First U.S. Cases with Orthofix fiberFUSE Strip Bone Graft
fiberFUSE Strip is formulated to enable optimized application for posterior cervical, posterior lumbar and degenerative spinal procedures.
July 13, 2021

Bioventus Launches OSTEOAMP SELECT Flowable in the U.S.

Bioventus Launches OSTEOAMP SELECT Flowable in the U.S.
The bone graft substitute was developed for a variety of procedures including lumbar spine, cervical spine and foot & ankle fusion.
April 21, 2021

8 Orthopedic Companies New On Our Radar

8 Orthopedic Companies New On Our Radar
These companies recently received notable FDA 510(k) clearances, funding or launched products and studies. We highlight robotics/digital, spine and orthobiologic applications.

Member-Only Content

SUBSCRIBE Login
April 14, 2021

Ventris Launches Next Generation Allocell AF Biologic

Ventris Launches Next Generation Allocell AF Biologic
Allocell AF is designed with broad, augmented bone fibers that maximize the surface area, allowing the fibers to better fill the defect site.
April 14, 2021

Hensler Surgical Obtains CE Mark Approval for Hensler Bone Press

Hensler Surgical Obtains CE Mark Approval for Hensler Bone Press
The press uses a 2-step technique to harvest autologous material during bony decompressions such as laminectomy, vertebral corpectomy, foot/ankle surgery, etc.
April 14, 2021

Kuros Biosciences Treats First Patient in Clinical Trial of MagnetOs Putty

Kuros Biosciences Treats First Patient in Clinical Trial of MagnetOs Putty
Kuros Biosciences treated the first patient in a prospectively designed, randomized controlled U.S. trial named PROOF, comparing MagnetOs Putty to autograft for posterolateral spine fusion. This Level 1 quality trial will be the first such U.S. clinical study of MagnetOs for spinal fusion....
February 2, 2021

First Case with TheraCell TheraFuze DBF Fiber Wrap

First Case with TheraCell TheraFuze DBF Fiber Wrap
DBF Fiber Wrap is a lyophilized sheet comprising 100% demineralized cortical bone fibers that can be rehydrated with saline, blood or bone marrow.
January 21, 2021

OrthogenRx Looks to Stay Nimble with Patient Payment Programs

OrthogenRx Looks to Stay Nimble with Patient Payment Programs
OrthogenRx markets GenVisc 850 and TriVisc biologic products. OrthogenRx executes at a level of efficiency that allows them to invest in pricing programs.
January 12, 2021

Surgalign Launches ViBone Moldable Cellular Bone Matrix

Surgalign Launches ViBone Moldable Cellular Bone Matrix
ViBone Moldable, provided by Aziyo Biologics, is a next-generation viable cell bone matrix optimized to protect and preserve the health of native bone cells.
December 29, 2020

Collagen Matrix Acquires Resorbable Synthetic Bone Grafts

Collagen Matrix Acquires Resorbable Synthetic Bone Grafts
The transaction includes GUIDOR bone graft substitutes known as easy-graft and calc-i-oss, and builds on the company's strategy to expand its technologies.
November 20, 2020

TheraCell Announces Royalty Milestone From Licensing

TheraCell Announces Royalty Milestone From Licensing
TheraCell licensed the technology to AlloSource to market AlloFuse Cortical Fibers and AlloFuse Fiber Boats, and to produce private-label products.
November 17, 2020

AlloSource Completes ProChondrix Study Milestone

AlloSource Completes ProChondrix Study Milestone
First patients completed 12-month follow-up in its prospective, multi-center study of ProChondrix CR to repair knee articular cartilage defects.
November 10, 2020

Royal Biologics Launches Fibri-Cell Cortical Fibers

Royal Biologics Launches Fibri-Cell Cortical Fibers
FIBRI-CELL with Osteo-Spin technology offers a novel approach to enhance traditional bone graft substitutes for orthopedic fusion procedures.
November 5, 2020

Cerapedics Launches i-FACTOR+ Matrix in Canada

Cerapedics Launches i-FACTOR+ Matrix in Canada
i-FACTOR+ Matrix is now fully available in Canada through distributor Surgi-One, and can be used in both spine and general orthopedic applications.
October 5, 2020

Artoss Hits Record Sales of NanoBone Bone Graft

Artoss Hits Record Sales of NanoBone Bone Graft
NanoBone bone grafting material incorporates nano-crystalline hydroxyapatite particles that are similar in size, chemistry and morphology to HA particles of human bone.
October 5, 2020

MagnetOs Bone Grafts Approved in Australia

MagnetOs Bone Grafts Approved in Australia
MagnetOs Granules and MagnetOs Putty received TGA approval in Australia. Initial market launch is scheduled for late 1Q21.
September 24, 2020

Spine Wave Launches Tornado Bioactive Bone Graft Matrix

Spine Wave Launches Tornado Bioactive Bone Graft Matrix
Tornado synthetic and bioactive bone graft alternative is delivered to the surgical site safely and quickly using the GraftMag Graft Delivery System.
September 15, 2020

Cerapedics Gains Canadian Approval of Next-Gen Bone Graft

Cerapedics Gains Canadian Approval of Next-Gen Bone Graft
Canada will be the first commercial market to launch i-FACTOR+ Matrix. The technology is currently being studied in an FDA IDE trial targeting lumbar fusion.
September 2, 2020

Royal Biologics Acquires FIBRINET Platelet-Rich Fibrin Matrix

Royal Biologics Acquires FIBRINET Platelet-Rich Fibrin Matrix
Fibrinet enables safe and rapid preparation of Platelet-Rich Fibrin Membrane and Platelet-Rich Fibrin Gel from a small sample of blood at the point of care.
July 24, 2020

5 Orthopedic Companies New on Our Radar

5 Orthopedic Companies New on Our Radar
These entities may have received funding, a first FDA 510(k) clearance, made acquisitions or entered into partnerships.

Member-Only Content

SUBSCRIBE Login
July 22, 2020

Cerapedics Gains FDA Approval of IDE Supplement

Cerapedics Gains FDA Approval of IDE Supplement
The IDE Supplement allows for a reduction in the number of patients required to be enrolled in the ASPIRE IDE Study on P15-L bone graft in the lumbar spine.
July 22, 2020

Osteopore Developing 3D-Printed Bone Implant

Osteopore Developing 3D-Printed Bone Implant
The technology has shown encouraging early results for regrowth of long bone defects in patients who have lost more than six centimeters of bone.
July 22, 2020

Kuros Biosciences Granted Patents in Europe and Japan

Kuros Biosciences Granted Patents in Europe and Japan
The patents cover combinations of polymers and granular materials and further expand Kuros' patent portfolio relating to its MagnetOs product.
July 20, 2020

Wright Medical Update on AUGMENT Reimbursement

Wright Medical Update on AUGMENT Reimbursement
The transitional pass-through payment reimburses outpatient centers and ASCs for incremental cost of AUGMENT in hindfoot and ankle fusion.
July 15, 2020

Spine Wave Launches Tempest Allograft Bone Matrix

Spine Wave Launches Tempest Allograft Bone Matrix
The limited market release of Tempest Allograft Bone Matrix marks Spine Wave's entry into the spinal biologics market.
July 7, 2020

Collagen Solutions in New Agreement with NovaBone

Collagen Solutions in New Agreement with NovaBone
The companies have collaborated since 2015 to develop collagen-based bone graft products used in orthopedic and dental applications.
June 30, 2020

Aziyo Biologics Launches OsteGro V Bone Matrix

Aziyo Biologics Launches OsteGro V Bone Matrix
The product expands Aziyo's regenerative medicine portfolio and leverages proprietary processing to protect and preserve native bone cells.
June 15, 2020

BONESUPPORT Completes Trial Enrollment

BONESUPPORT Completes Trial Enrollment
Enrollment of the FORTIFY study on CERAMENT G has been completed, with 198 subjects enrolled. BONESUPPORT expects to submit a PMA application in late 2021.
March 18, 2020

Orthobiologics Face Pressure from Lack of Clinical Evidence

Orthobiologics Face Pressure from Lack of Clinical Evidence
In the race to capitalize on patient-driven interest in stem cells, biologic solutions and “regeneration” of a more vital, healthy and functional body, there has been an explosion of offerings that lack scientific controls, validity and meaningful evidence.
March 10, 2020

NuVasive Attrax Putty Study Results

NuVasive Attrax Putty Study Results
Study results support the use of NuVasive's Attrax® Putty as a standalone bone graft substitute for autograft in instrumented thoracolumbar posterolateral lumbar fusion.
January 21, 2020

Anika Therapeutics Takes Major Step in Strategic Transformation with Acquisition of Parcus Medical and Arthrosurface

Anika Therapeutics Takes Major Step in Strategic Transformation with Acquisition of Parcus Medical and Arthrosurface
With the acquisitions of Parcus Medical and Arthrosurface, Anika looks ready to complete a major step in its five-year strategic plan to become a leader in joint preservation and restoration.

Member-Only Content

SUBSCRIBE Login
January 7, 2020

Bone Biologics Study Shows Bone Formation in Spine Model

Bone Biologics Study Shows Bone Formation in Spine Model
Preclinical animal study results indicate that Bone Biologics' rhNELL-1 growth factor effectively promoted bone formation in a spine model. 
December 13, 2019

In2Bones Launches AlloAid BioNail Implant

In2Bones Launches AlloAid BioNail Implant
In2Bones commenced global launch of the AlloAid BioNail™ engineered allograft implant for reconstructive surgery of the hand and foot.
November 25, 2019

Arthrosurface Introduces SpiralUp TCL Allograft

Arthrosurface Introduces SpiralUp TCL Allograft
Arthrosurface launched SpiralUp™, a talocalcaneal allograft system to treat peritalar subluxation and other injuries resulting in instability in the subtalar joint.
July 25, 2019

FDA 510(k) Recap: Spinal Devices and Technologies from 1H19

With the NASS 2019 Annual Meeting approaching, it's an ideal time to revisit spine products that have gained FDA 510(k) clearance in the first half of the year. This round-up shares another entrant into the sacroiliac joint treatment arena, an implant company's first clearance for an enabling technology and additional details about some lesser-known companies to watch.
July 18, 2019

SeaSpine Expands OsteoStrand DBM Fiber Portfolio

SeaSpine introduced a new integrated open-bore hydration syringe for OsteoStrand and OsteoStrand Plus Demineralized Bone Fibers.
June 21, 2019

Royal Biologics Gains Funding

Royal Biologics, developer of products for regenerative medicine, received funding to support employee onboarding, operational growth, product development and acquisitions. 
April 11, 2019

BONESUPPORT: Study Affirms Cerament Remodels into Human Bone

Retrospective review of 163 patients at one-year follow-up revealed clinical evidence of BONESUPPORT's CERAMENT® bone void filler remodeling into bone in humans.
March 27, 2019

Bioventus Launches OSTEOAMP SELECT Fibers

Bioventus introduced OSTEOAMP® SELECT Fiber allograft bone graft substitute for spine, foot/ankle, orthopedic and trauma procedures.
February 28, 2019

Medtronic Launches Grafton DBM in Japan

Medtronic launched Grafton Demineralized Bone Matrix in Japan for spine and orthopedic procedures. 
November 26, 2018

SurGenTec Launches GraftGun with ViBone Viable Bone Matrix

SurGenTec completed initial clinical launch of the GraftGun bone graft delivery system combined with ViBone Viable Bone Matrix prefilled tubes.
November 19, 2018

Innovasis Signs Private-Label Agreement with Stability Biologics

Innovasis entered into a private-label agreement with Stability Biologics that includes access to Physio® bone allograft. Product launch is expected by year-end.
November 13, 2018

Arthrex Collaborates with CellRight Technologies on Distribution

CellRight Technologies, a Tissue Regenix company, entered into an agreement granting Arthrex distribution rights to its BioRinse bone portfolio in Europe.
September 27, 2018

Baxter Receives FDA Clearance for ALTAPORE Bone Graft

Baxter was granted FDA 510(k) clearance to market ALTAPORE Bioactive Bone Graft as an autograft extender in posterolateral spinal fusion.
September 24, 2018

NuVasive Launches New Orthobiologic Products

NuVasive commenced U.S. launch of three new biologic products for spine, including traditional bone allograft, an amniotic membrane and new formats in the Propel Demineralized Bone Matrix line. 
August 10, 2018

Wright Medical Reports 2Q18 Revenue

Wright Medical reported 2Q18 revenue of US $205.4MM, +14.3% from 2Q17, and 1H18 revenue of $403.9MM, +13.2% vs. 1H17.

Member-Only Content

SUBSCRIBE Login
August 1, 2018

SeaSpine 2Q18 Revenue +7% vs. 2Q17

SeaSpine announced 2Q18 revenue of US $36.4MM, +6.5% vs. 2Q17, and 1H18 revenue of $69.6MM, +5.3% vs. 1H17. This is the company's highest quarterly growth rate since its spinoff from Integra LifeSciences in 2015.

Member-Only Content

SUBSCRIBE Login
July 16, 2018

Cerapedics Closes $22MM Financing

Cerapedics completed a US $22MM financing. Proceeds will support commercialization and a U.S. lumbar trial of i-FACTOR bone graft.
July 16, 2018

Artoss Completes $1MM Funding Round

Artoss completed a US $1MM funding round. Proceeds will support development of new NanoBone® bone graft products for the U.S. market, regulatory requirements and commercialization.
April 4, 2018

RTI Surgical Reaches Milestone for Sterilization Processes

RTI Surgical reached a global milestone of >8 million biologic implants processed through proprietary sterilization, with no confirmed incidence of implant-associated infection.
March 5, 2018

SeaSpine Announces 4Q17, 2017 Revenue

SeaSpine announced 4Q17 revenue of US $34.0MM, +4.5% vs. 4Q16, and 2017 revenue of $131.8MM, +2.3% vs. 2016. 

Member-Only Content

SUBSCRIBE Login
November 8, 2017

SeaSpine Reports 3Q17 Revenue

SeaSpine announced 3Q17 revenue of US $31.7MM, flat vs. 3Q16, and YTD revenue of $97.8MM, +1.6% vs. the prior year.

Member-Only Content

SUBSCRIBE Login
November 8, 2017

Wright Medical 3Q17 Revenue +8% YoY

Wright Medical reported 3Q17 revenue of US $170.5MM, +8.4% from 3Q16, and YTD revenue of $527.4MM, +6.0% vs. the prior year.

Member-Only Content

SUBSCRIBE Login
September 25, 2017

HCT Regenerative to Distribute LifeLink Allografts in Taiwan

LifeLink Tissue Bank will provide allografts to treat sports, orthopaedic and spine injuries to HCT Regenerative, for distribution in Taiwan. 
September 18, 2017

Artoss Enters DAPA Agreement for NanoBone Graft Products

Artoss entered into a Defense Acquisition Purchasing Agreement with Owens & Minor for U.S. Department of Defense access to NanoBone bone graft.
September 6, 2017

Centric Medical Posts 112% Growth Within Foot & Ankle

Centric Medical announced record revenue growth of TARSA-LINK™ Stand-Alone Wedge Fixation, ROGUE™ Hammertoe Correction, OSTEO-LINK® 100% DBM and MARROW CELLUTION™ Bone Marrow Harvesting systems.

Member-Only Content

SUBSCRIBE Login
August 24, 2017

Bone Biologics Expands Relationship with UCLA

Bone Biologics entered into an exclusive license agreement with UCLA for global application of NELL-1 protein in the treatment of osteoporosis and trauma, through a technology transfer. 
June 27, 2017

ChoiceSpine Launches Biologics Portfolio

ChoiceSpine launched a biologics portfolio, adding allograft, synthetic bone graft and amnion offerings to complement its spinal hardware portfolio.
May 25, 2017

SurGenTec Receives US Patent for GRAFTGUN

SurGenTec was granted U.S. Patent No. 9,655,748, Bone Graft Delivery System and Method for Using Same, pertaining to the GRAFTGUN® device.
May 15, 2017

Curasan Launches CERASORB Ortho Foam in the US

CURASAN entered the U.S. market with the first U.S. implantation of CERASORB® Ortho Foam bone graft.
May 9, 2017

SeaSpine Posts 1Q17 Revenue

SeaSpine announced 1Q17 revenue of US $31.9MM, +1.6% vs. 1Q16. (U.S. $28.6MM, +0.2%; ex-U.S. $3.3MM, +15.6%)

Member-Only Content

SUBSCRIBE Login
May 4, 2017

TheraCell Issued U.S. Patent for Enhanced Cancellous Bone

TheraCell was issued U.S. Patent No. 9,636,436, "Compositions of and Methods for Cancellous Bone Matrix," addressing its ECS™ enhanced cancellous demineralized bone technology.
March 2, 2017

FDA 510(k) Clearance for NanoFUSE BA

Amend Surgical received FDA 510(k) clearance to market NanoFUSE® BA as a bone graft extender for spine and orthopaedic applications.
October 26, 2016

TheraCell and AlloSource Issued U.S. Patent for Bone Fiber Technology

TheraCell announced pending issuance of a U.S. patent for DBF™ demineralized bone fiber, part of AlloSource's AlloFuse® Cortical Fibers and AlloFuse® Fiber Boats.
September 23, 2016

Spineology Expands Relationship with Musculoskeletal Transplant Foundation

The Musculoskeletal Transplant Foundation is now sole tissue provider for Spineology's allograft product lines, including the newly-launched Incite™ Cortical Fiber bone graft.
July 26, 2016

Pre-clinical Study Results: Multipotent Adult Progenitor Cells on an Allograft Scaffold

Pre-clinical studies suggest that multipotent adult progenitor cells (MAPCs), such as the technology used in RTI Surgical's map3® Cellular Allogeneic Bone Grafts, exhibited a more robust angiogenic protein release profile vs. mesenchymal stem cells in vitro.
July 6, 2016

Preclinical Study Validates Science Behind AlloSource AlloStem Cellular Bone Allograft

Preclinical data on adipose-derived mesenchymal stem cells in a rat model, using technology similar to AlloSource's AlloStem® Cellular Bone Allograft process, showed bone formation within a critical-sized defect in all study subjects.
May 17, 2016

Novastep and Vivex Biomedical to Launch bioSTART Biologics

Novastep signed an agreement with Vivex Biomedical to launch bioSTART® Tissue Repair products, offering amniotic membranes and liquid to support foot and ankle procedures in the U.S.
March 2, 2016

Bioventus New Product Launches

At AAOS 2016, Bioventus is introducing the CellXtract™ novel cell and bone marrow extraction tool and SIGNAFUSE™, a bioactive bone graft putty. 
February 29, 2016

Bone Biologics Completes $5.75 Million Funding Round

Bone Biologics completed a US $5.75MM funding round to support development of a bone graft substitute for initial focus on spinal fusion.
January 11, 2016

MiMedx to Acquire Stability Biologics

MiMedx signed a definitive agreement to acquire Stability Biologics for US $10MM in cash and stock. Stability Biologics provides human tissue products for the surgical, spine and orthopaedic industries. The transaction is expected to close in early 1Q16.